by Clinical Neuropsychologist | Wednesday, February 5, 2025 | Dementia
Abstract INTRODUCTION The Alzheimer’s Association Global Biomarker Standardization Consortium conducted a blinded case–control study to learn which phosphorylated tau (p-tau) assays provide the largest fold-changes in Alzheimer’s disease (AD) versus non-AD...
by Clinical Neuropsychologist | Wednesday, February 5, 2025 | Dementia
Abstract INTRODUCTION Research on somatic and germline mutations in Chinese individuals with early-onset Alzheimer’s disease (EOAD) has been limited. METHODS We conducted whole-genome sequencing of blood DNA from 108 patients with EOAD and 116 controls. The...
by Clinical Neuropsychologist | Wednesday, February 5, 2025 | Dementia
Abstract INTRODUCTION This study aimed to investigate the differential roles of various plasma biomarkers in a stepwise diagnostic strategy for Alzheimer’s disease (AD). METHODS A total of 2984 participants, including 666 cognitively unimpaired (CU), 2032 with...
by Clinical Neuropsychologist | Monday, February 3, 2025 | Dementia
Abstract INTRODUCTION Identifying the link between early Alzheimer’s disease (AD) pathological changes and neurodegeneration in asymptomatic individuals may lead to the discovery of preventive strategies. We assessed longitudinal brain atrophy and cognitive...
by Clinical Neuropsychologist | Thursday, January 30, 2025 | Dementia
Abstract INTRODUCTION The phase 3 trial CLARITY AD found lecanemab slowed cognitive decline by 27%. However, subgroup analyses indicated a significant 31% sex difference in the effect and suggested no or limited effectiveness in females. We used simulations...
by Clinical Neuropsychologist | Wednesday, January 29, 2025 | Dementia
Alzheimer’s &Dementia, EarlyView. If you do not see content above, kindly GO TO SOURCE. Not all publishers encode content in a way that enables republishing at Neuro.vip. This post is Copyright: | January 29, 2025 Wiley: Alzheimer’s & Dementia:...
